Literature DB >> 12540373

Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis.

Nathalie Pamir1, Francis C Lynn, Alison M J Buchan, Jan Ehses, Simon A Hinke, J Andrew Pospisilik, Kazumasa Miyawaki, Yuichiro Yamada, Yutaka Seino, Christopher H S McIntosh, Raymond A Pederson.   

Abstract

The incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are gut hormones that act via the enteroinsular axis to potentiate insulin secretion from the pancreas in a glucose-dependent manner. Both GLP-1 receptor and GIP receptor knockout mice (GLP-1R(-/-) and GIPR(-/-), respectively) have been generated to investigate the physiological importance of this axis. Although reduced GIP action is a component of type 2 diabetes, GIPR-deficient mice exhibit only moderately impaired glucose tolerance. The present study was directed at investigating possible compensatory mechanisms that take place within the enteroinsular axis in the absence of GIP action. Although serum total GLP-1 levels in GIPR knockout mice were unaltered, insulin responses to GLP-1 from pancreas perfusions and static islet incubations were significantly greater (40-60%) in GIPR(-/-) than in wild-type (GIPR(+/+)) mice. Furthermore, GLP-1-induced cAMP production was also elevated twofold in the islets of the knockout animals. Pancreatic insulin content and gene expression were reduced in GIPR(-/-) mice compared with GIPR(+/+) mice. Paradoxically, immunocytochemical studies showed a significant increase in beta-cell area in the GIPR-null mice but with less intense staining for insulin. In conclusion, GIPR(-/-) mice exhibit altered islet structure and topography and increased islet sensitivity to GLP-1 despite a decrease in pancreatic insulin content and gene expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12540373     DOI: 10.1152/ajpendo.00270.2002

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  34 in total

1.  Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors.

Authors:  Frédéric Preitner; Mark Ibberson; Isobel Franklin; Christophe Binnert; Mario Pende; Asllan Gjinovci; Tanya Hansotia; Daniel J Drucker; Claes Wollheim; Rémy Burcelin; Bernard Thorens
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

2.  Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism.

Authors:  Burton M Wice; Songyan Wang; Dan L Crimmins; Kelly A Diggs-Andrews; Matthew C Althage; Eric L Ford; Hung Tran; Matthew Ohlendorf; Terry A Griest; Qiuling Wang; Simon J Fisher; Jack H Ladenson; Kenneth S Polonsky
Journal:  J Biol Chem       Date:  2010-04-26       Impact factor: 5.157

3.  Type 2 diabetes increases oocyte mtDNA mutations which are eliminated in the offspring by bottleneck effect.

Authors:  Li Li; Chang-Sheng Wu; Guan-Mei Hou; Ming-Zhe Dong; Zhen-Bo Wang; Yi Hou; Heide Schatten; Gui-Rong Zhang; Qing-Yuan Sun
Journal:  Reprod Biol Endocrinol       Date:  2018-11-03       Impact factor: 5.211

4.  DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice.

Authors:  Siri Malmgren; Bo Ahrén
Journal:  Diabetologia       Date:  2015-02-09       Impact factor: 10.122

Review 5.  Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.

Authors:  Marzieh Salehi; Benedikt A Aulinger; David A D'Alessio
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

6.  Double incretin receptor knock-out (DIRKO) mice present with alterations of trabecular and cortical micromorphology and bone strength.

Authors:  A Mieczkowska; S Mansur; B Bouvard; P R Flatt; B Thorens; N Irwin; D Chappard; G Mabilleau
Journal:  Osteoporos Int       Date:  2014-08-16       Impact factor: 4.507

7.  The role of apolipoprotein A-IV in regulating glucagon-like peptide-1 secretion.

Authors:  Fei Wang; Qing Yang; Sarah Huesman; Min Xu; Xiaoming Li; Danwen Lou; Stephen C Woods; Corina Marziano; Patrick Tso
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-08-20       Impact factor: 4.052

Review 8.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

9.  Glucose intolerance and reduced proliferation of pancreatic beta-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function.

Authors:  Simone Renner; Christiane Fehlings; Nadja Herbach; Andreas Hofmann; Dagmar C von Waldthausen; Barbara Kessler; Karin Ulrichs; Irina Chodnevskaja; Vasiliy Moskalenko; Werner Amselgruber; Burkhard Göke; Alexander Pfeifer; Rüdiger Wanke; Eckhard Wolf
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

10.  The Incretins and Pancreatic beta-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus.

Authors:  Mi-Hyun Kim; Moon-Kyu Lee
Journal:  Korean Diabetes J       Date:  2010-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.